Companies/Denali Therapeutics Inc.

Company profile

Denali Therapeutics Inc.

NASDAQ: DNLI · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001714899Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

51D

FH 54DQ 61GM 15SS 71

v0.1 · 65/100 weight · provisional

↑ market scale, balance-sheet leverage · ↓ 3-yr revenue growth, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$512.5M

Employees

443

Market cap

$4.1B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$512.5M-$512.5M2025

Operating income-$555.3M-$555.3M2025

Total assets$1.1B$1.1B2025

Liabilities$131.1M$131.1M2025

Equity$1.0B$1.0B2025

Revenue trend

FY2019 – FY2025 · USD

$13.6M

FY19

$26.7M

FY19

$335.6M

FY20

$48.7M

FY21

$105.1M

FY22

$330.5M

FY23

FY24

FY25

Revenue by segment

Filed disclosures · FY2020

By product

Alzheimer's Disease Services100%

By geography

Not disclosed.

The read

Denali Therapeutics Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Doximity, Inc.73B Concentra Group Holdings Parent, Inc.68B iRhythm Technologies, Inc.75B+Merit Medical Systems, Inc.83B+

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B87A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B73B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEORyan J. Watts

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: DNLI

Employees443

IPO date2017-12-08

Latest filings

8-K2026-06-18 8-K2026-06-04 8-K2026-05-22 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-21 8-K2026-04-03 8-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.